Epix amends EP-2104R clinical trial protocols
This article was originally published in Clinica
Executive Summary
Epix Pharmaceuticals has amended phase II proof-of-concept clinical trial protocols relating to the development of EP-2104R, its injectable fibrin-targeted imaging agent, designed to detect blood clots under MRI.